PDS Biotechnology Corp EDGE Cash Flow

Pds biotechnology corp (EDGE)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15
Cash flows from operating activities:
Net income (loss)
-3,985	-4,177	-5,751	-3,885	6,816	-1,819	-711	-567	-737	-13,903	-11,281	-13,504	-12,170	-9,515	-10,759	-9,376	-9,170	-7,959	-10,130	-5,520	-4,468
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
124	245	120	18	2,754	817	-2	44	7	1,545	1,570	1,580	1,485	1,275	1,233	1,380	1,415	1,332	611	583	371
Stock-based 401K company common match
9	7	4	25	0	0	0	0	0	46	49	0	121	0	0	0	0	-	-	-	-
Depreciation expense
3	-	-	-	18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
-	-	-	-	-	-	7	7	7	48	47	44	42	39	28	16	15	14	14	14	9
Impairment of machinery and equipment
-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
Bargain purchase gain
0	1,395	0	209	11,729	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Increase in warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,433	350	96
Amortization of debt discount
-	-	-	-	-	-	-	-	-	3	6	9	12	15	17	20	22	24	26	26	26
Amortization of debt issuance costs
-	-	-	-	-	-	-	-	-	27	27	27	27	27	23	18	21	94	0	0	0
Non-cash interest expense
-	-	-	-	-	-	-	-	-	89	90	91	92	93	65	8	8	9	10	10	8
Changes in assets and liabilities:
Prepaid expenses and other assets
570	3,047	-1,751	-338	181	69	-14	-4	-15	659	-310	-62	-255	594	-370	-111	-151	892	-16	-124	62
Accounts payable
1,358	-456	-364	-536	-620	544	72	155	16	1,422	-1,348	1,767	-943	1,820	-689	-553	842	54	1,076	-442	-760
Accrued expenses
122	-	-607	11	-304	-	-81	-60	288	2,139	-871	637	303	792	813	98	-2,381	537	1,941	-852	515
Restructuring reserve
-228	-360	-425	-664	-121	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-3,164	-5,519	-4,327	-4,858	-3,367	-317	-432	-415	-404	-9,240	-11,399	-9,283	-10,773	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Cash received in reverse merger transaction
0	0	0	0	29,106	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,073	-	-4,998	-5,705	-4,265
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	27	55	16	89	347	144	118	77	505	352	361	86
Net cash provided by investing activities
0	275	0	0	29,106	0	0	0	0	-27	-55	-16	-89	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-77	-	-352	-361	-86
Proceeds from issuance of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,000
Proceeds from stock option exercise
-	-	-	-	-	-	-	-	-	26	0	41	50	0	267	25	0	1	0	0	0
Proceeds from exercise of warrants
70	-	-	-	0	-	-	-	-	2	47	0	3	7	10	2	0	-	-	-	-
Payments for issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-4	549	928	234	189	50
Payments for debt back end fees
-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
Repayments of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	0	381	559	547	533	0	0	0
Proceeds from issuance of shares, gross
11,970	0	0	0	750	50	173	0	1,055	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of capital lease obligation
-	-	-	-	-	4	3	3	3	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of preferred stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	52,425	-31
Net cash provided by financing activities
12,040	0	0	0	750	278	169	-3	1,052	28	47	22,423	54	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
8,876	-5,244	-4,327	-4,858	26,489	-38	-262	-418	648	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,095	-	-234	52,236	2,917
Net decrease in cash
-	-	-	-	-	-	-	-	-	-9,239	-11,407	13,123	-10,808	-6,385	1,762	-8,920	-10,247	77,309	-5,585	46,169	-1,433
Supplemental disclosure of cash flow information:
Cash paid for:
Interest
0	-0	0	0	0	0	-0	1	0	462	467	362	343	-	-	-	-	-	-	-	-
Interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	133	-	147	160	104
Supplemental cash flow information:
Conversion of convertible notes and accrued interest into common stock
0	0	0	0	32	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Consideration in connection with reverse merger transaction
0	0	0	0	15,793	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred issuance costs included in accrued expenses and accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	518	12	21
Accrued capital expenditures included in accrued expenses and accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-181	-181	525	5	-505	309	183	83